tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MRUS Stock Latest News

Merus’s Oncology Potential and Financial Stability Justify Buy Rating
RatingsMerus’s Oncology Potential and Financial Stability Justify Buy Rating
13h ago
MRUS
Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for Head and Neck Cancer
PremiumCompany Announcements
Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for Head and Neck Cancer
6d ago
MRUS
Merus N.V.’s Promising Phase 3 Study on Head and Neck Cancer Treatment
PremiumCompany Announcements
Merus N.V.’s Promising Phase 3 Study on Head and Neck Cancer Treatment
6d ago
MRUS
Merus initiated with a Buy at Alliance Global Partners
PremiumThe Fly
Merus initiated with a Buy at Alliance Global Partners
19d ago
MRUS
Merus N.V. Reports Q2 2025 Financial Results
PremiumCompany Announcements
Merus N.V. Reports Q2 2025 Financial Results
24d ago
MRUS
Merus’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating
PremiumRatingsMerus’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating
1M ago
MRUS
Optimistic Buy Rating for Merus Driven by Future Data on Petosemtamab in CRC
Premium
Ratings
Optimistic Buy Rating for Merus Driven by Future Data on Petosemtamab in CRC
1M ago
MRUS
Merus’s Strategic Advances in Biotechnology: Buy Rating Driven by Promising mCRC Data Outlook and Innovative Trial Designs
Premium
Ratings
Merus’s Strategic Advances in Biotechnology: Buy Rating Driven by Promising mCRC Data Outlook and Innovative Trial Designs
1M ago
MRUS
Merus reports Q2 EPS ($2.23), consensus ($1.15)
PremiumThe Fly
Merus reports Q2 EPS ($2.23), consensus ($1.15)
1M ago
MRUS
Merus sees cash runway at least into 2028
PremiumThe Fly
Merus sees cash runway at least into 2028
1M ago
MRUS
Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for HNSCC Treatment
PremiumCompany Announcements
Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for HNSCC Treatment
1M ago
MRUS
Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study
PremiumCompany Announcements
Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study
2M ago
MRUS
Truist biotech analyst holds an analyst/industry conference call
PremiumThe FlyTruist biotech analyst holds an analyst/industry conference call
2M ago
JNJ
EXEL
Merus N.V.’s MCLA-129 Study: A Potential Game-Changer in Cancer Treatment
Premium
Company Announcements
Merus N.V.’s MCLA-129 Study: A Potential Game-Changer in Cancer Treatment
3M ago
MRUS
Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know
Premium
Company Announcements
Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know
3M ago
MRUS
3 Best Stocks to Buy Now, 6/12/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 6/12/2025, According to Top Analysts
3M ago
ACMR
MRUS
Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target
PremiumRatings
Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target
3M ago
MRUS
Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability
PremiumRatings
Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability
3M ago
MRUS
Merus Announces Public Offering of Common Shares
PremiumCompany Announcements
Merus Announces Public Offering of Common Shares
3M ago
8K
MRUS
Trump says Fed ‘must now’ lower rates after ADP payrolls report: Morning Buzz
PremiumThe FlyTrump says Fed ‘must now’ lower rates after ADP payrolls report: Morning Buzz
3M ago
C
BLK
Merus 5.27M share Spot Secondary priced at $57.00
Premium
The Fly
Merus 5.27M share Spot Secondary priced at $57.00
3M ago
MRUS
Merus’s Promising Clinical Developments and Market Potential Justify Buy Rating
Premium
Ratings
Merus’s Promising Clinical Developments and Market Potential Justify Buy Rating
3M ago
MRUS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >